A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study
| Autor: | Masumi Hayashi, Eriko Takeshita, Toshiyuki Hibuse, Tohru Funahashi, Takekazu Kimura, Ayumu Hirata, Ken Kishida, Akemi Oka, Norikazu Maeda, Yasuhiko Nakagawa, Tomoko Minami, Hitoshi Nishizawa, Iichiro Shimomura, Susumu Kashine |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Time Factors endocrine system diseases medicine.medical_treatment Endocrinology Diabetes and Metabolism Pilot Projects Inctrein law.invention Sitagliptin Phosphate DPP4 inhibitor Randomized controlled trial Asian People law Internal medicine Diabetes mellitus medicine Sitagliptin Humans Prospective Studies Prospective cohort study Original Investigation Aged Dipeptidyl-Peptidase IV Inhibitors Adiponectin business.industry Insulin Diabetes Body Weight Type 2 Diabetes Mellitus nutritional and metabolic diseases Middle Aged Triazoles medicine.disease Endocrinology Treatment Outcome Diabetes Mellitus Type 2 Oxidative stress Pyrazines Female business Cardiology and Cardiovascular Medicine Biomarkers medicine.drug |
| Zdroj: | Cardiovascular Diabetology |
| ISSN: | 1475-2840 |
| Popis: | Background The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including sitagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM). Adiponectin, an adipocyte-derived circulating protein, has anti-atherosclerotic and anti-diabetic properties and is effectively elevated in bloodstream by thiazolidinediones, an insulin sensitizer. However, the effect of sitagliptin treatment on serum adiponectin level in T2DM has not fully elucidated in Japanese T2DM patients. The aim of the present study was to examine the effect of sitagliptin treatment on serum adiponectin levels in T2DM subjects. Methods Twenty-six consecutive Japanese T2DM outpatients were recruited between April 2011 and March 2013, and randomized into the control (conventional treatment, n = 10) group and sitagliptin treatment group (n = 16). Serum adiponectin was measured by enzyme-linked immunosorbent assay. Results Indices of glycemic control, such as hemoglobin A1c, glycated albumin, and 1.5-anhydro-D-glucitol, were significantly improved after the three-month treatment in both the control and sitagliptin groups. Serum adiponectin level was significantly increased in sitagliptin group from 6.7 ± 0.8 to 7.4 ± 1.0 μg/mL without change of body mass index (p = 0.034), while serum adiponectin level was not altered in the control group (p = 0.601). Conclusion In Japanese T2DM patients, serum adiponectin level was elevated by three-month treatment with sitagliptin without change of body weight. Trial registration UMIN000004721 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink